Recommendation from Healthcare and Software & IT Services Sector

The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations. [EasyDNNnews:PaidContentStart]

MANKIND PHARMA LTD
CMP - ₹3,001.30
BSE CODE 543904
Volume 26,226
Face Value ₹1
Target ₹3,240 - ₹3,300
Stoploss ₹2,790 (CLS)

The company is one of India’s leading pharmaceutical companies, known for its diverse portfolio spanning prescription medicines, OTC products, and consumer healthcare. With popular brands like Manforce, Prega News, AcneStar and Gas-O-Fast, it has carved a strong market presence. In Q2FY25, the company showcased notable performance, achieving a 14 per cent growth in total revenue to ₹3,077 crore, while net profit surged around 30 per cent year-on-year to ₹656 crore.

The stock attracted significant buying interest following its recent announcement to raise nearly ₹3,000 crore through a Qualified Institutions Placement (QIP) of equity shares. The equity shares will be allotted to eligible Qualified Institutional Buyers (QIBs) at an issue price of ₹2,520 per share. Given the company’s robust market presence, strong financial performance, and recent developments with the potential to drive stock growth, we recommend BUY.

Vakrangee Ltd
CMP - ₹31.68
BSE CODE 511431
Volume 31,82,564
Face Value ₹1
Target ₹34 - ₹35
Stoploss ₹29 (CLS)

The company is a technology-driven entity focused on creating India’s largest network of last-mile retail outlets to serve the unserved and underserved populations. Nextgen Vakrangee Kendras, functioning as ‘One Stop Shops,’ provide a wide range of products and services across multiple sectors, including BFSI, ATMs, E-Commerce, and Logistics, catering to diverse customer needs. In Q2FY25, it demonstrated remarkable growth, with total revenue growing by 27 per cent to ₹65 crore, compared to ₹52 crore in Q2FY24. Net profit also climbed 37 per cent year-on-year, from ₹0.43 crore to ₹0.59 crore.

The company announced that its board approved the issuance of 35 crore convertible warrants through a preferential allotment to 11 non-promoter investors, aiming to raise ₹980 crore, subject to shareholder approval. Despite market weakness, the stock has soared over 35 per cent in a month, demonstrating strong growth potential. Therefore, we recommend BUY.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

[EasyDNNnews:UnPaidContentEnd]